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INTRODUCTION
In this issue of Molecular Medicine, we
assembled a series of articles on the use
of histone deacetylase (HDAC) inhibitors
(HDACi’s) in the treatment of a broad
spectrum of diseases not related to can-
cer. Presently, the spectrum of diseases
being evaluated are mostly inflammatory
or autoimmune in nature. However,
orally active drugs that are safe and anti-
inflammatory are ideal for treating
chronic degenerative diseases (1). The in
vitro and in vivo studies of HDACi’s in
models of inflammatory and autoim-
mune diseases have required doses con-
siderably lower than the concentrations
of HDACi’s that are required to bring
about the death of malignant cells in vitro
and in tumor-bearing mice. This charac-
teristic of an effective low dose suggests
that the traditional mechanism of action
of HDACi’s (that is, hyperacetylation of
nuclear histones with increased expres-
sion of proapoptotic genes) may not ac-
count for the antiinflammatory proper-
ties of HDACi’s. Acetylation of
cytoplasmic proteins may explain the
unique properties of low doses of
HDACi’s. In this issue of Molecular Medi-
cine, each contribution considers the
amelioration of disease severity in a spe-
cific pathological model and proposes
the likely mechanism of action of
HDACi’s.
As cytokine-driven inflammation plays
a fundamental role in nearly all acute as
well as chronic diseases, targeting cy-
tokines in metabolic, neurodegenerative,
cardiovascular, bowel and joint diseases
has become a major area of investigation
(1). The importance of cytokines in the
pathogenesis of these diseases has been
validated by the widespread use of anti-
cytokine monoclonal antibodies and now
includes Type 1 and 2 diabetes, as re-
viewed by Mandrup-Poulsen et al. (2),
Donath and Shoelson (3), and Dinarello
et al. (4). The attractive aspect of
HDACi’s is that they are orally active,
and low concentrations are most effec-
tive in reducing inflammation in humans
(5) and animal models (6).
The success of HDACi’s in the treat-
ment of inflammatory diseases will de-
pend on two factors: lack of organ toxic-
ity and tolerability as well as the
specificity of the inhibitor for the rele-
vant HDAC in a particular pathological
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process. Indeed, the future development
of HDACi’s should be focused on selec-
tive inhibitors, since there are 18 distinct
HDACs (7). It is also expected that inhi-
bition of specific HDACs will offer opti-
mal efficacy depending on the dominant
cell type in a particular disease, for ex-
ample, reducing interferon (IFN)-γ pro-
duction by a specific HDAC in T cells.
For inflammatory diseases such as gouty
arthritis or Type 2 diabetes, inhibition of
interleukin (IL)-1β production or secre-
tion would best use an HDACi that regu-
lates caspase-1.
HISTORICAL BACKGROUND
HDACi’s were initially studied for
their ability to increase gene expression.
Phenylbutyrate was used for many
years to increase gene expression of
fetal hemoglobin in patients with a ge-
netic basis for anemia. Phenylbutyrate
also has an excellent safety record. Oral
phenylbutyrate was used in children
and adults with sickle cell disease. De-
spite the increment in hemoglobin F
and reticulocytes, the use of 30–40 cap-
sules a day is not an optimal therapy
(8,9). Today, however, the increasing
number of orally active, synthetic
HDACi’s are primarily developed to
treat cancer. The development of
HDACi’s for treatment of cancer is
based on de-repression of genes that
participate in endogenous proapoptotic
pathways and bring about a selective
death of malignant cells while sparing
healthy cells. By use of this mechanism,
HDACi’s would avoid the toxic effects
of many chemotherapeutic drugs. It
was Paul Marks and his coworkers that
brought the first HDACi to be ap-
proved, suberoylanilide hydroxamic
acid (SAHA). SAHA (generically
vorinostat) and romidepsin (FK228) are
approved for the treatment of cuta-
neous T-cell lymphoma (CTCL). Similar
to other HDACi’s, SAHA and FK228 in-
crease several genes that induce apo-
ptosis in malignant cells and are consis-
tent with the well-studied mechanism
of all HDACi’s (that is, hyperacetyla-
tion of nuclear histones).
With hyperacetylation of nuclear his-
tones, chromatin unravels and transcrip-
tion factors can now bind to DNA and
initiate the synthesis of RNA coding for
proapoptotic genes. For the most part,
the doses of vorinostat and romidepsin
used to treat humans with cancer are
based on maximal tolerated doses. It is
assumed that plasma levels reach those
concentrations observed for increased ex-
pression of proapoptotic genes in tumor
cells in vitro. Knowing the concentration
of a particular HDACi for inducing
apoptotic cell death in primary tumor
cells in vitro is often not possible, and the
success of any HDACi in the treatment
of humans with cancer is thus measured
by a reduction in the tumor burden.
However, in terms of the antiinflamma-
tory properties of HDACi’s, the in-
hibitors are studied in primary cells in
vitro. As stated, the most distinguishing
property of the antiinflammatory proper-
ties of HDACi’s is that significantly
lower concentrations are used in models
of autoimmune diseases compared with
those used to reduce tumors in mice. A
similar example exists for the inhibition
of cytokines in vitro. For example, the
50% inhibition of proliferation of A549
tumor cells requires 5 μmol/L, whereas
to inhibit 50% of IL-1β secretion requires
50 nmol/L in freshly obtained human
peripheral blood mononuclear cells
(PBMCs) (10), and similar data have
been reported for ITF2357 (11). Thus,
when considering the efficacy of an
HDACi to treat a cytokine-driven inflam-
matory disease, it is possible to draw
some conclusions that the in vivo efficacy
is related to an in vitro concentration and,
because of the lower concentrations,
more likely to be achieved in vivo.
As discussed in the various reports in
this issue, HDACi’s also hyperacetylate
nonhistones such as cytosolic proteins,
including transcription factors them-
selves. Because HDACs deacetylate the
highly conserved N-terminal lysines
present on histones, it is also appropriate
to use KDACi’s for lysine deacetylase in-
hibitors. In fact, it is likely that some
mechanisms by which HDACi’s are ef-
fective in reducing disease severity in an-
imal models of inflammation and im-
mune disorders are due to acetylation of
cytoplasmic proteins and not nuclear his-
tones, although hyperacetylation of both
likely take place at the same time. Com-
plexes of HDAC with histones as well as
cytoplasmic proteins in the same cell
challenges the concept that targeting spe-
cific HDACs with small-molecule
HDACi’s may not result in the same ef-
fect or results in the same therapeutic
 advantage.
In general, HDACs are nonredundant.
A knockdown of class I HDACs with
siRNA resulted in cellular changes simi-
lar to those observed with small-mole-
cule HDACi’s (12). In mice deficient in
HDAC-6, there is hyperacetylation of
HDAC-6, but otherwise the mice are
healthy. Mice with null mutations for
HDAC-1 do not progress beyond embry-
onic stages (13), whereas mice deficient
in HDAC-2 succumb to an early death
because of hyperproliferation of car-
diomyocytes (13). For example, mice de-
ficient in HDAC-2 die with cardiomy-
opathy. HDAC-8-deficient mice die soon
after birth because of malformations in
calvarial and facial bones (14). A null
mutation in HDAC-3 in the liver dis-
rupts normal metabolic homeostasis (15).
The deletion of HDAC-8 as with other
HDAC deletion studies suggests that
HDAC functions to suppress either the
ability of particular transcription factors
active during embryonic development or
the expression and synthesis of other
transcription factors, which serve to sup-
press genes. Silencing of HDAC-1,
HDAC-2 or HDAC-3 by using siRNA de-
creased IFNγ-inducible genes, whereas
overexpression of these same HDACs in-
creased signal transducers and activators
of transcription (STAT)-1-dependent
genes (16).
HDACi’s REDUCE THE PRODUCTION OF
PROINFLAMMATORY CYTOKINES
For reducing disease severity in sev-
eral immune and inflammatory condi-
tions, synthetic glucocorticoids remain
the mainstay of therapies. However, with
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specific antibodies to cytokines such as
tumor necrosis factor (TNF)-α, IL-1β,
IL-6 receptors and others, anticytokine-
based therapies have found a place in the
treatment of autoimmune diseases such
as rheumatoid arthritis, inflammatory
bowel disease, psoriasis and several oth-
ers. Reducing the activity of IL-1β has
had a major impact on the treatment of
autoinflammatory diseases (17). Without
question, neutralization of specific cy-
tokines has canonized their causative
role in inflammation and has changed
the lives of millions of patients with
these diseases (1). Compared with the
metabolic consequences of long-term
glucocorticoids, anticytokine therapies
are a major improvement in treating an
increasing number of diseases, but par-
enteral administration is a major draw-
back of anticytokine therapy, and de-
creased host defense against infection is
another. Nevertheless, anticytokine ther-
apy is nearly devoid of organ toxicity.
Because inflammation plays a fundamen-
tal role in nearly all chronic inflamma-
tory and degenerative diseases, in-
hibitors of proinflammatory cytokine
production as well as activities has be-
come a major area of investigation for
orally active drugs. As summarized in
Table 1, orally active HDACi’s are effec-
tive in reducing cytokines in vitro and in
various animal models.
SAHA was developed to treat cancer,
but in studies published in 2002, we
added SAHA to freshly obtained human
peripheral blood mononuclear cells
(PBMCs) stimulated with lipopolysac-
charide (LPS) (10). There was 50% reduc-
tion in TNFα, IL-1β, IL-12 and IFNγ at
100–200 nmol/L, a 20-fold lower concen-
tration that that required for inhibition of
tumor cell proliferation in vitro. When
stimulated with the combination of IL-12
plus IL-18, IFNγ was reduced by 85%.
Steady-state mRNA levels for LPS-
 induced TNFα and IFNγ were markedly
decreased, whereas levels for IL-8 and
IL-1β mRNA were unaffected. Although
the levels of the IL-1β precursor were not
decreased, secretion of IL-1β was re-
duced at 100–200 nmol/L.
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Table 1. Properties of HDACi’s for treating disease not related to cancer.
Systemic inflammation
Reviewed in (79)
Improved survival after hemorrhage (89)
Decreased cytokinemia after systemic endotoxin (10,11,136)
Decreased NO production (6,10,32)
Protection against hepatitis after intravenous concanavalin A (11)
Suppression of vascular cell adhesion molecule-1 expression (137)
In vitro cytokine production
Decreased gene expression and synthesis of LPS-induced TNFα and IFNγ in human 
peripheral blood mononuclear cells (10,11,138)
Decreased IL-1β-induced IL-6 in synovial cells and human blood monocytes (23)
Reduced IFNγ in mouse trophoblasts (139)
Decreased production of IL-6 in PBMCs stimulated with IL-12 plus IL-18 (11)
Decreased secretion of IL-1β (10,11,52)
Decreased IL-12 and IL-17 production from monocytes and dendritic cells (10,20,50)
Decreased IL-6 from stromal cells (104)
Reduced IL-1β-induced PGE2 and NO in human chrondrocytes (140)
Decreased ischemia-induced retinal TNFα production (141)
Downregulation of IL-12 transcription in transformed lung epithelial cells (142)
Increased PGD2 production and suppression of matrix metalloproteinases (82)
Suppression of c-jun and transcription of COX-2 (83)
Models of inflammatory bowel disease
Reviewed in (74)
Reduced disease severity in dextran sodium sulfate and trinitrobenzene sulfonic acid 
(TNBS) colitis (143,144)
Decreased cytokine levels in colitis model (143,144)
Reduced severity of colitis in HDAC-9-deficient mice (145)
Suppression of COX-2 activation in colon cells (146)
Immunosuppressive properties
Reviewed in (43,75,76)
Survival benefit in GvHD (71,72,147)
Sparing effect on graft versus leukemia (71)
Increased Foxp3+ T-regulatory cells (148,149)
Reduced incidence of diabetes in NOD mouse (36)
Induction of antigen-specific anergy in lymphocytes (150)
Improved allograft transplantation (148,151)
Induction of IDO and inhibition of dendritic cell maturation (44)
Reduced nephritis in lupus-prone mice (119,120)
Decrease disease severity in experimental allergic encephalitis (76,152)
Suppression of Th1 polarization of murine dendritic cells (153)
Inhibition of IL-2 gene expression in T cells (154,155)
Reduced cytokine production in primary human T cells stimulated with anti-CD3/CD28 (156)
Inhibition of CD154 (CD40L) expression in T cells (157)
Models of arthritis
Reviewed in (25,26)
Reduced joint destruction in collagen-induced arthritis (25,158,159)
Decreased bone and cartilage loss (25)
Lower cytokine and chemokine levels (23,24)
Decreased synovial cell proliferation (160)
Abrogation of TGFβ-1-induced fibroblast-myofibroblast differentiation (161)
Inhibition of IL-1β-induced matrix metalloproteinase expression in human articular 
chondrocytes (162)
Continued
A single oral dose of SAHA to mice be-
fore LPS dose-dependently reduced cir-
culating TNFα, IL-1β, IL-6 and IFNγ. The
effect of HDACi’s on cytokine production
was also studied with ITF2357 (generic
givinostat) (11). In PBMCs, ITF2357 re-
duced by 50% the release of TNFα at con-
centrations of 10–20 nmol/L, the intracel-
lular levels of IL-1α at 12 nmol/L, the
secretion of IL-1β at 12.5–25 nmol/L and
the production of IFNγ at 25 nmol/L.
Similar to SAHA (10), there was no re-
duction in IL-8 in these same cultures. By
using the combination of IL-12 plus
IL-18, IFNγ and IL-6 production was re-
duced by 50% at 12.5–25 nmol/L. There
was no evidence of cell death in LPS-
stimulated PBMCs at 100 nmol/L
ITF2357, by using assays for DNA degra-
dation, annexin V and caspase-3/7.
There was a 50% to 90% reduction in
LPS-induced steady-state levels of TNFα
and IFNγ but no reduction of IL-1β or 
IL-8 (11). Similar to SAHA, the secretion
of IL-1β was reduced, suggesting that
ITF2357 affects caspase-1 and proteins
that are required for activation of
 caspase-1 (18). Although neither SAHA
nor ITF2357 reduced the chemokine IL-8,
ITF2357 did reduce surface CXCR4 and
CCR5 expression on CD4+ T cells and
monocytes (19).
In related studies, human PBMCs
were differentiated into dendritic cells,
and the effect of the HDACi tricho-
statin A (TSA) as well as SAHA was in-
vestigated on the production of IL-12
and IL-17. There was a reduction of 86%
and 83%, respectively, by SAHA. In
these differentiated dendritic cells, the
T-cell chemokines CXCL9, -10 and -11
were also reduced (20). Oral adminis-
tration of 1.0–10 mg/kg ITF2357 to
mice reduced LPS-induced serum
TNFα and IFNγ by >50%. However,
anti–CD3- induced cytokines were not
suppressed by ITF2357 in PBMCs ei-
ther in vitro or in the circulation in
mice. In concanavalin-A–induced hepa-
titis, 1 mg/kg oral ITF2357 significantly
reduced liver damage at the same level
as 5 mg/kg. In mice subjected to
 streptozotocin-induced diabetes, an oral
dose of 2.5 mg/kg provided protection
(6). Thus, low, nonapoptotic concentra-
tions of the HDAC inhibitor ITF2357 re-
duce proinflammatory cytokine produc-
tion in primary cells in vitro and exhibit
antiinflammatory effects in vivo. In con-
trast, treatment of murine macrophages
with the histone deacetylase inhibitor
LAQ824 induced chromatin changes in
the IL-10 gene promoter that results in
recruitment of the transcriptional re-
pressor HDAC11 (21). This result dimin-
ishes IL-10 production and induction of
inflammatory cells. These results are in-
consistent with the antiinflammatory
properties of HDACi’s.
Panobalinostat (LBH589) was tested for
treatment of multiple myeloma and lym-
phomas. At clinically relevant concentra-
tions added to cultured human dendritic
cells (DC), LBH589 reduced the surface
molecule expression on immature and
mature DCs, which was associated with
DC maturation, antigen presentation and
T-cell costimulation (22). LBH589 also sig-
nificantly reduced the production of
TNFα, IL-6, IL-10, IL-12 and IL-23 stimu-
lated with LPS. It was also reported that
the RelB component of nuclear factor
(NF)-κB had a critical role in the antiin-
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Table 1. Continued.
Heart failure
Reviewed in (63)
Reduced Hop-mediated hypertrophy and heart failure (163)
Decreased left ventricular cardiac hypertrophy (164)
Reduced cardiac arrhythmias in dystrophic mice (165)
Brain and neurological systems
Reviewed in (77) and (76)
Improved neurological recovery after closed head trauma (93)
Reduced gliosis and neuronal apoptosis (93,166)
Decreased neuroinflammation in glial cells (41)
Reduced brain infarct after cerebral artery occlusion (115,167,168)
Decreased disease severity in models of Huntington disease (96,97,99)
Reduced loss of function in ALS model (169,170)
Effects in multiple sclerosis (76,152)
Models of diabetes
Reviewed in (34)
Decreased death in IL-1β-induced pancreatic insulin-producing β cells (6,32-35,171)
Decreased death in IL-1β-induced insulin-producing INS cells (32,34,35)
Protection from streptozotocin-induced diabetes (6)
Decreased islet cytokine production (6)
Inhibition of IL-1β-induced NO production by pancreatic islets (6,32,34,35)
Fibrotic diseases
Prevention of renal interstitial fibrosis after ureteral obstruction (172)
Decreased left ventricular cardiac hypertrophy (164)
Increased basic morphogenic protein 7 in the regenerative response to renal ischemia (173)
Reduced fibrotic changes in tubulointerstitial injury (174)
Inhibition of hypoxia-induced angiogenesis (175)
Decreased TGFβ-1-induced renal injury (176)
Suppression of epithelial-to-mesenchymal transition induced by TGFβ (177)
Muscular dystrophy
Reviewed in (78)
HIV-1 purging
Reviewed in (38)
In vitro studies (19,38,132,133)
Studies in humans (116,131)
flammatory and immunosuppressive
mechanism of this HDACi (22).
Because there are 18 separate second
coding for HDAC, the specificity of an
HDACi for a particular HDAC or a clus-
ter of related HDACs likely affects its
mechanism of action for reducing inflam-
mation via inhibition of cytokines.
ITF2357, SAHA and generally all
 hydroxamate-based HDACi’s do not in-
hibit sirtuins, 7 of the 18 known HDACs.
Another consideration is the cell target
being affected by HDAC inhibition. Al-
though it can be assumed that all
HDACi’s enter the cell by a simple con-
centration gradient in that there are no
specialized membrane channels required
for entry, the antiinflammatory mecha-
nism is cell specific for the disease model.
For example, in rheumatoid arthritis the
fibroblast-like synoviocyte plays an im-
portant role in the pathological processes
of joint destruction. These cells produce
several cytokines, both inflammatory as
well as antiinflammatory, chemokines
and prostaglandins. When stimulated
with IL-1β, the fibroblast-like synoviocyte
produces copious amounts of IL-6, a
known growth factor for the invasive
pannus of joints in rheumatoid arthritis.
HDACi’s reduce IL-1β-driven IL-6 pro-
duction as well as reduce synovial cell
survival (23). The mechanism for the re-
duction in IL-6 production is an acceler-
ated degradation of IL-6 mRNA rather
than inhibition of components of NFκB
signaling (24). As reported in this issue,
HDACi’s suppress IL-1β-driven loss of
bone and cartilage (25), and the targets
are the chondrocyte and osteoclast, since
these are key pathways for destructive
joint disease in both rheumatoid arthritis
as well as osteoarthritis (26).
HDACi’s FOR INHIBITION OF CYTOKINE
SIGNALING
Many studies on HDACi’s focus on in-
hibition of LPS-induced cytokine produc-
tion. Some of these reports are listed in
Table 1. Although the LPS pathway as
well as all Toll-like receptor (TLR) ago-
nists are commonly studied with
HDACi’s, the signaling pathway is pri-
marily in myeloid lineage cells such as
monocytes and macrophages. These cells
are, without doubt, major players in in-
flammation because of infections; but,
most human disease is due to sterile in-
flammation. In the models of sterile in-
flammation, a hypoxic event is often the
trigger and, with hypoxia, there is cell
death and the release of cell contents. As
such, cytokines and other intracellular
components initiate the inflammatory
trigger. For example, IL-1α and HMGB1
are inflammatory molecules that are re-
leased from dead cells and are highly in-
flammatory (27–29). In autoimmune dis-
eases, the trigger for inflammation is not
via the TLR pathway but rather via cy-
tokines such as IL-17 (30). In Type 1 dia-
betes, IL-1β is highly toxic, inducing cell
death of the insulin-producing β cells as
well as nitric oxide (NO) (2). Similarly,
IL-1β is toxic for the β cell in Type 2 dia-
betes (3). In bone loss, IL-1β and TNFα
are the stimulators of osteoclast activa-
tion. Therefore, suppression of cytokine
signaling may be the more relevant anti-
inflammatory mechanism for HDACi’s
rather than TLR-induced cytokines.
Diabetes
Because targeting IL-1β-mediated in-
flammation protects islets in human trials
(31,32), the use of oral HDACi’s to target
islet inflammation should be considered
for both Type 1 and Type 2 diabetes. In
vitro HDACi’s reduced cytokine-
 mediated NO formation and the decline
in insulin secretion in isolated rat islets
(32,33). Whereas the initial studies on the
antiinflammatory effects of HDACi’s fo-
cused on a reduction in the production of
IL-1β, TNFα, IFNγ and other proinflam-
matory cytokines from LPS-stimulated
freshly obtained human PBMCs, other
investigators examined the ability of
HDACi’s to inhibit cytokine-induced ef-
fects. If HDACi’s are to be used to treat a
broad spectrum of inflammatory as well
as autoimmune diseases,  cytokine-driven
inflammation is more relevant than in-
flammation driven by microbial prod-
ucts. Indeed, sterile inflammation is cer-
tainly the dominant cause of disease,
particularly cardiovascular disease. For
example, safe and specific antiinflamma-
tory agents are sought for the prevention
of cytokine-induced destruction of pan-
creatic islet β cells. The immune-
 mediated elimination of pancreatic
β cells in Type 1 diabetes involves release
of cytotoxic cytokines such as IL-1β and
IFNγ, which induce β-cell death in vitro
by mechanisms that are both dependent
and independent of NO (2). SAHA (10)
inhibits IL-1β-induced NO in mouse
macrophages and also in rat primary
islet cells and the INS insulinoma cell
line (32). SAHA reduced the cytokine-
mediated decrease in insulin secretion
and increase in iNOS levels, NO forma-
tion and apoptosis (32). A similar effect
of ITF2357 was observed on IL-1β-
 stimulated mouse and rat primary islets
and the INS cell line (6). Although there
was no effect of SAHA on IL-1β-
 mediated degradation of IκB or binding
of NFκB to DNA, SAHA reduced the sec-
ond phase of NFκB phosphorylation (32).
As reviewed in detail, HDAC inhibition
prevents cytokine-induced β-cell apopto-
sis and impaired β-cell function (34).
In vivo, during streptozotocin-induced
β-cell destruction, ITF2357 protected the
insulin-producing β cell following an oral
dose of 1.25–2.5 mg/kg (6). Serum NO
levels returned to nondiabetic values,
islet function improved and glucose
clearance increased. In vitro, at 25 and 250
nmol/L, ITF2357 increased islet cell via-
bility, enhanced insulin secretion, inhib-
ited chemokine production and reduced
IL-1β-induced iNOS levels. In peritoneal
macrophages and splenocytes, ITF2357
inhibited the production of NO, as well
as that of TNFα and IFNγ at a 50% (me-
dian) inhibiting concentration IC50 of
25–50 nmol/L (6). Thus, at clinically rele-
vant doses, the orally active HDAC in-
hibitor ITF2357 favors β-cell survival dur-
ing inflammatory conditions.
The nonobese diabetic (NOD) mouse is
often used as the model for Type 1 dia-
betes in humans. Because the HDACi’s
SAHA, ITF2357 or TSA protect the
 insulin-producing pancreatic β cell in
primary rat islets (6,32,33,35), in primary
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mouse islets (6) or the rat insulinoma cell
line (6,32,35), it was not unexpected that
inhibition of HDACs by TSA adminis-
tered once a week was reported for re-
ducing the incidence of diabetes that
consistently develops in these mice (36).
Also, not unexpectedly, there was a re-
duction in cellular infiltration of islets
with a return of normoglycemia. Al-
though these studies demonstrate a ben-
eficial effect of TSA, it was reported that
splenic T lymphocytes derived from pro-
tected mice resulted in enhanced expres-
sion of IFNγ mRNA and protein (36), and
there were no changes in the expression
of inducible NO, IL-17 or TNFα. These
findings are highly inconsistent with the
known beneficial effects of suppression
of IFNγ activities, not only for the NOD
mouse (37) but also for the property of
HDACi’s to reduce IFNγ production
(6,10,11) and also on the property of
HDACi’s to suppress STAT-1 activities
(16). Moreover, the combination of IL-1β
plus IFNγ is highly toxic to the β cell and
is prevented by SAHA and ITF2357
(6,32).
EFFECT OF HDACi’s ON CHEMOKINE
RECEPTORS
In several models of inflammation, in-
filtration of neutrophils is characteristic
and the chemotactic chemokine IL-8
plays an important role. However, de-
spite the suppression of TNFα and IFNγ
gene expression in PBMCs stimulated
with LPS in the presence of SAHA (10) or
ITF2357 (11), there is no reduction in IL-8
gene expression or protein levels. Rather,
it appears that HDACi’s reduce
chemokine receptors. PBMCs from seven
healthy donors were incubated in the
presence of ITF2357 or valproic acid, and
after 4 and 24 hours, there was a de-
crease in CCR4 of 47% (P < 0.001) and
54% (P < 0.001), respectively, at therapeu-
tic concentrations (38). Consistent with
the reduction of surface CXCR4 expres-
sion, steady-state mRNA levels of
CXCR4 after 2 and 4 hours, as measured
by RT-PCR, were reduced by 65% in cul-
tures treated with 250 nmol/L ITF2357
compared with control cultures. There
was also a marked decreased expression
of CCR5 on CD14-positive blood mono-
cytes (38). Others have reported that
HDACi’s decrease CXCR4 protein and
mRNA levels in leukemia cell lines and
lymphoblasts from patients with child-
hood acute leukemia (39).
MOLECULAR MECHANISMS OF ACTION
OF HDACi’s RELATED TO
ANTIINFLAMMATORY PROPERTIES
Each of the 14 reports in this issue pro-
poses a molecular mechanism for the
ability of HDACi’s to reduce the severity
of disease in animal models or in cul-
tured cells. There is no single unifying
molecular mechanism. As reviewed by
Christensen et al. (34), NFκB received a
great deal of attention for its role in cy-
tokine induction of cytokines. If one ex-
amines the effects of IL-1β on the insulin-
producing pancreatic β cell, >2,000 genes
are modified (34). Since HDACi’s reduce
the effects of NFκB activity- dependent
genes, for example IL-1-induced IL-6 or
inducible NO synthetase (35), it seems
logical that the primary mechanism of
action is inhibition of NFκB functions.
However, although several reports indi-
cate that HDACi’s do reduce NFκB activ-
ity, electrophoretic mobility shift assay
did not reveal such a mechanism in
IL-1β-exposed cells in the presence of
SAHA or TSA (32). The failure to observe
a reduction in NFκB activity was also re-
ported for primary human synovial fi-
broblasts stimulated with IL-1β for the in-
duction of IL-6 (24). IL-1β induces a
biphasic phosphorylation of inhibitor
protein IκBα with the second peak re-
duced by HDACi’s (32). However, no ef-
fect was observed on IκBα degradation
or NFκB binding to DNA. Thus, it ap-
pears that HDAC inhibition prevents the
cytokine-mediated effects by downregu-
lating NFκB transactivating activity (40).
In non–β cells, IFNγ-induced JAK activa-
tion and STAT-1 activity depends on
HDAC-1, -2 and -3 activity (16).
Some studies demonstrate that
HDACi’s prevent the phosphorylation of
IκB with downstream suppression of
gene expression after TLR or cytokine
stimulation. For example, IL-1β-induced
phosphorylation of IκB is reduced by
SAHA, suggesting that the antiinflam-
matory properties of HDACi’s may by
due to reduced NFκB activity (32,35). As
discussed below, other studies suggest
that HDACi’s hyperacetylate NFκB. An-
other possible mechanism is the ability of
HDACi’s to acetylate STAT-3. SAHA in-
creases histone H3 acetylation in the nor-
mal mouse brain accompanied by in-
creased expression of the neuroprotective
proteins Hsp70 and Bcl-2.
Because HDACi’s increase gene expres-
sion, one possible mechanism of action is
the induction of genes that are themselves
inhibitors of inflammation, for example,
induction of transforming growth factor
(TGF)-β, IL-10 or IL-1 receptor antagonist.
Suppressors of cytokine signaling-1 and -
3 (SOCS1/3) have broad antiinflamma-
tory and immunosuppressive properties,
and HDACi’s increase the expression of
SOCS-3 (41). Other studies show that
HDACi’s impair the binding of c-Fos and
c-Jun to DNA, thus inhibiting gene ex-
pression induced by activator protein-1
(AP-1).
Histone deacetylase 6 (HDAC-6) is a
mostly cytoplasmic class II HDAC that
has a unique structure with two catalytic
domains and a domain-binding ubiquitin
with high affinity. This HDAC acetylates
α-tubulin and heat shock protein
(Hsp)-90. HDAC-6 was targeted by ho-
mologous recombination, and HDAC-6-
deficient mice are viable, are fertile and
show hyperacetylated tubulin in most
tissues. Lymphoid development is nor-
mal, but the immune response is moder-
ately affected. Furthermore, the lack of
HDAC-6 results in a small increase in
cancellous bone mineral density. Thus,
these data demonstrate that mice survive
well without HDAC-6 and that tubulin
hyperacetylation is not detrimental to
normal mammalian development.
Protein lysine acetylation is a post-
translational mechanism involved in all
aspects of cell homeostasis. Indeed, a
growing number of nonhistone proteins
are targets of histone acetyltransferase
(HAT) and HDAC. Acetylation affects
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thousands of cellular proteins, both cyto-
plasmic and nuclear (42). Among these
proteins, transcription factors are broadly
involved in the molecular mechanisms
influenced by HDACi’s. An example of
acetylation of a transcription factor by
HDACi’s is STAT-3, as reviewed by Choi
and Reddy (43). Both ITF2357 and SAHA
induce the indoleamine 2,3-dioxygenase
(IDO), which prevents dendritic cell mat-
uration and is regulated by STAT-3 (44).
STAT-3 suppresses transcription of IFNγ
and IL-17 and increases production of
IL-10. Individuals with a mutation in
STAT-3 suffer from hyper IgE syndrome,
resulting in failure to control inflamma-
tion; disease severity in these patients is
consistent with studies showing that
STAT-3 suppresses cytokines. Activation
of STAT-3 can take place by acetylation,
and acetylated STAT-3 enhances STAT-3
dimer and thereby activity. ITF2357 and
SAHA induce acetylation of STAT-3 in
dendritic cells at concentrations that are
achievable in humans (44).
As a posttranslational mechanism, the
effects of lysine acetylations on cell func-
tions are broad. Over 3,600 lysine acetyla-
tion sites were identified on 1,750 pro-
teins, and the acetylations due to SAHA
and MS-275 were studied (45). It was re-
ported that lysine acetylation preferen-
tially targets large macromolecular com-
plexes and that acetylation impaired
phosphorylation-dependent interactions
(45). The reversible acetylation of key ly-
sine residues plays a fundamental role in
the function of NFκB (46). The interaction
of NFκB (47,48) with acetyl transferase
and deacetylase enzymes has many func-
tional consequences. Reversible acetyla-
tion of distinct lysine residues has both
positive and negative regulatory effects
on nuclear NFκB activities, including
transcriptional activation, DNA binding
affinity, IκB association and subcellular
localization. Since NFκB plays a major
role in orchestrating the inflammatory re-
sponse, its regulation by acetylation has
been the subject of various studies aimed
at elucidating the antiinflammatory
mechanism of HDACi’s. Chen et al.
showed that histone deacetylase 3
deacetylates lysine 218 and 221 of p65
and promotes its high affinity binding to
IκBα in the nucleus. This complex is rap-
idly exported from the nucleus to reestab-
lish the latent cytoplasmic pool ready to
be activated upon a new stimulation.
Maintenance of lysines 218 and 221 in an
acetylated state prolongs the nuclear ac-
tivity of NFκB. Thus, from this study, it
seems that preserving HDAC3 activity in
the nucleus would lead to a blockade of
NFκB activity, in apparent contradiction
with the effect exerted by pan-HDACi’s
on proinflammatory  response.
The contradictory effect of HDAC in-
hibition on the activity of NFκB is also
evident from the work of Kiernan et al.
(49), who showed that, in a different cel-
lular system, the acetylation of p65 took
place on different lysine residues,
namely Lys122 and Lys123. Moreover,
the acetylation of p65 reduced its ability
to bind DNA and facilitated its removal
from DNA and consequently its IκB-
 mediated export from the nucleus.
HDAC-3 was shown to be the main iso-
form able to deacetylate p65, but in this
case, inhibition of HDAC-3 would lead
to repression of NFκB activity. Inhibition
of NFκB is not a necessary property for
an HDACi to be antiinflammatory. In
murine dendritic cells, TSA and vorinos-
tat strongly reduced the late expression
of TNFα but did not affect IL-1β produc-
tion or mitogen-activated protein kinase
activation (50).
Inhibition of proinflammatory re-
sponses induced by Toll-like receptor ac-
tivation by HDACi’s certainly relies on
multiple targets, but strongly depends on
cell type and stimulation. The status of
the same gene may differ from one cell
to another, and its activation or inhibi-
tion may take place with different kinet-
ics. The TLR4 signaling complex acti-
vates three main intracellular pathways:
the NFκB signaling pathway, interferon-
related factor (IRF) signal transduction
pathways and the mitogen-activated pro-
tein kinase (MAPK) cascade. Inhibition
of the latter with p38 kinase inhibitors
has been proven to strongly attenuate the
proinflammatory innate immune re-
sponse. As expected, the MAPK cascade
is regulated at multiple levels, one of
which relies on the deactivation of its
components by specific phosphatases.
MAPK phosphatases (MKPs) are dual-
specificity phosphatases that inactivate
MAPK members by dephosphorylating
phosphotyrosine and phosphothreonine
residues. In a recent report, Cao et al. (51)
demonstrated that MKP-1 is subjected to
regulation by reversible acetylation.
Acetylated MKP-1 has enhanced binding
to p38 and phosphatase activity, thereby
reducing the level of active phosphory-
lated p38. The direct consequence of the
increased activity of MKP-1 is the damp-
ening of TLR-mediated inflammatory re-
sponse. Inhibition of HDAC activity by
TSA reduced the expression of TNFα, 
IL-6, and IL-1β in LPS-stimulated
macrophages in an MKP-1-dependent
manner (51). In the same study, the au-
thors also showed the inhibition of NOS2
in Raw cells by TSA. NOS2 is a transcrip-
tional target of NFκB, which was not in-
fluenced by TSA treatment.
The role of the cytoplasmic HDAC-6 in
the regulation of inflammatory response
was investigated on the basis of the ra-
tionale that its inhibition would lead to
an altered microtubule network and re-
duced secretion of proinflammatory cy-
tokines such as IL-1β (52). Although the
necessity of a functional cytoskeleton
and microtubule network was estab-
lished in this work, no clear relationship
between HDAC-6 inhibition and IL-1β
secretion was found. The effect of HDAC
inhibition on IL-1β secretion is relevant
in that activation of caspase-1 via the in-
flammasome is required for the matura-
tion of IL-1β (53). Thus, inhibition of
gene expression of a critical component
of the inflammasome could be envisaged
as a mechanism responsible for the activ-
ity of HDACi’s on IL-1β secretion. More-
over, acetylation of inflammasome com-
ponents could be an important
posttranslational mechanism involved in
its assembly and activity.
HDAC-6 contributes to the regulation
of TLRs and IL-1β-induced signaling.
Once again, the activity of a deacetylase
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enzyme (HDAC-6), instead of its inhibi-
tion, appears to be necessary to down-
modulate the proinflammatory program
induced by TLRs and the IL-1 receptor.
The study showed that HDAC-6 and se-
questosome 1 (SQSTM1) were required
for MyD88 aggregation and lead to inhi-
bition of TLR ligand-induced expression
of IL-6 and NOS2 in RAW264.7 cells.
HDAC-6 and SQSTM1 partially sup-
pressed the activation of p38 and JNK,
but they had no effect on degradation of
IκB (54). According to these findings, in-
hibition of HDAC-6 would lead to en-
hanced MyD88 signal transduction activ-
ity. This result would be the logical
consequence of the use of an HDAC-6 in-
hibitor, such as vorinostat, in a LPS-
 induced septic shock model. A recent re-
port (55), showed that administration of
vorinostat (50 mg/kg intraperitoneally)
after a lethal dose of LPS significantly
improved long-term survival and re-
duced the expression of TNFα and IL-6.
The authors also observed that vorinos-
tat reduced the increased expression of
MyD88 caused by LPS administration
and postulated that this may be the di-
rect consequence of the decreased ex-
pression of MyD88-associated proinflam-
matory genes.
A large number of studies have shown
that inhibition of HDAC activity leads to
repression of different TLR-induced re-
sponses, mainly on the basis of analysis
of the expression of proinflammatory cy-
tokines. Two reports have analyzed the
effect of HDAC inhibition using a more
comprehensive approach on the basis of
whole genome expression analysis. Brog-
don et al. (56) showed that the potent
pan-HDACi LAQ824 exhibited a rather
selective activity on macrophages and
dendritic cells stimulated with LPS. The
inhibitor specifically inhibited DC-con-
trolled T helper 1 (Th1) effector but not
Th2 effector cell activation and migra-
tion. It also inhibited macrophage- and
DC-mediated monocyte but not neu-
trophil chemotaxis.
Roger et al. (57) confirm the concept of
HDACi’s as antiinflammatory drugs
through use of genome-wide microarray
analyses of macrophages and DC stimu-
lated with different TLR agonists. The
study revealed a critical role for HDACs
in the expression of host defense genes,
including pattern-recognition receptors,
costimulatory molecules, kinases, tran-
scription regulators, complement factors,
cytokines, chemokines and growth fac-
tors. The data suggest that HDACi’s exert
mainly an immunosuppressive effect but
also possess immunostimulatory activi-
ties. Interestingly, they suggest a novel ac-
tivity of HDACi’s, namely the induction
of the chromatin modifier Mi-2beta. Mi-2
is part of the nucleosome remodeling, his-
tone deacetylation (NuRD) complex. The
Mi-2β complex is selectively recruited
along with the other complexes to the
control regions of secondary response and
delayed primary response inflammatory
genes. In these complexes, the Mi-2β
 complex acts antagonistically to limit the
induction of these two gene classes. 
Mi-2β/NuRD inhibits LPS-induced sec-
ondary and delayed primary cytokine
production in macrophages and dendritic
cells (58). Thus, HDACi’s inhibit the ex-
pression of secondary response genes
such as IL-12, IL-6 and inducible NOS,
but have no effect or delayed effect on
primary genes such as IL-1β and TNFα,
respectively. Roger et al. also found that
TSA increased histone H4 acetylation of
IL-6 and IL-12 promoters, suggesting that
there was no correlation between the sta-
tus of histone acetylation and the ob-
served downregulatory effect of TSA on
gene transcription.
ARE HDACi’s CONTRAINDICATED IN
SOME DISEASES?
The third cause of death after cardio-
vascular disease and cancer is chronic
obstructive pulmonary disease (COPD).
Patients with COPD have a progressive,
unrelenting course, and various thera-
pies have not significantly reduced dis-
ease severity. Cytokines such as TNFα,
IL-18 and IL-32 are thought to play a role
in that these cytokines are elevated in
lung tissue of smokers with COPD but
not in smokers without COPD (59).
Chronic inflammation is believed to re-
sult in the loss of elasticity of the lung to
maintain the alveolar architecture. Alveo-
lar cell death is also believed to con-
tribute to the disease. In a large clinical
trial in patients with COPD, histone
HDAC expression and activity are re-
duced in the lung tissue (60). Mizuno et
al. (61) explored whether HDAC inhibi-
tion causes lung cell apoptosis and em-
physema in a rat model. Rats were
treated with TSA. Chronic TSA treatment
increased the alveolar air space area and
the number of caspase-3–positive cells in
rat lungs. TSA suppressed hypoxia-
 inducible factor-1α and vascular en-
dothelial growth factor (VEGF) gene ex-
pression in rat lungs as well as cultured
human pulmonary microvascular en-
dothelial cells. The study suggests that
administration of HDACi’s may worsen
the clinical course of COPD.
DOES THE USE OF HDACi’s INCREASE
THE RISK OF INFECTIONS?
The inhibition of a number of proin-
flammatory cytokines induced by micro-
bial products through TLR’s activation
by HDACi’s poses a question related to
the effect of the use of these inhibitors on
the occurrence of infections. Without a
doubt, all biologics used in patients with
various inflammatory diseases increase
risk of infection. Anti-TNFα monoclonal
antibodies (infliximab and adalimumab)
and the soluble TNF receptor etanercept
are associated with increased risk of op-
portunistic as well as routine infections
and deaths (reviewed by Dinarello [1]).
Blocking IL-1β with anakinra is not asso-
ciated with increased opportunistic infec-
tions and is considerably safer. Some bio-
logics are linked to progressive
multifocal leukencephalopathy. At the
present time, there are only two disease
conditions that are being treated with
HDACi’s: vorinostat in graft versus host
disease (GvHD) (43) and givinostat in
systemic-onset juvenile idiopathic arthri-
tis (SOJIA) (5). The GvHD study is un-
derway and there are no data at this
time, but there were no infections in the
SOJIA patients treated for 12 weeks with
givinostat. Moreover, these patients with
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SOJIA were concomitantly treated with
glucocorticoids at the same time. In the
phase I trial of givinostat, the decrease in
whole blood production of TNFα, IL-1β,
IL-6 and IFNγ was transient after a single
oral dose and returned to baseline levels
within 12 hours. In contrast, antibodies
to TNFα persist for several weeks and
are more likely to suppress host defense
than short-acting oral HDACi’s (62).
HDACi’s FOR HEART FAILURE
As reviewed in the report by McKin-
sey (63), there are several animal models
that result in the physiological character-
istics of human heart failure. Some are
related to inflammation associated with
cytokine-induced cell death and the loss
of myocytes, particularly secondary to
IL-1β (64,65). As a result, the ability of
the heart to effectively pump blood out
of its chambers is reduced, and the pa-
tients experience difficulties maintaining
normal activities. Heart failure is an
enormous economic burden on most so-
cieties, and with increasing numbers of
patients with Type 2 diabetes and in-
creased myocardial infarction, the inci-
dence of heart failure increases each year.
Having orally active HDACi’s as antiin-
flammatory agents is an attractive thera-
peutic option. The concept that TNFα
contributed to heart failure was based on
two observations: levels of TNFα were
elevated in the circulation of patients
with stage III and IV New York Heart
Association heart failure classification
and treating heart failure patients with
etanercept (a TNFα blocker) improved
exercise tolerance (66). However, in two
large studies, etanercept failed to provide
improvement and infliximab actually in-
creased mortality (67). Therefore, when
there is use of HDACi’s to combat heart
failure, a reduction in TNFα levels is not
considered beneficial.
On the other hand, studies have exam-
ined a role for IL-1β in the pathogenesis
of heart failure. Serum levels of IL-1β in
a large and representative population
were associated with congestive heart
failure (P > 0.001) and angina (P = 0.02),
with Ca2+ serum levels (P = 0.02) and
with a history of dyslipidemia (P = 0.05)
(68). The data from humans as well as
mice support the hypothesis from the
large epidemiologic studies that IL-1β is
mainly involved in the functional alter-
ations of cardiomyocytes (69). It is un-
likely that HDACi’s will be used as a
monotherapy in combating heart failure.
As outlined by McKinsey (63), there are
several drugs used to treat heart failure
but few target inflammatory pathways. It
is also likely that HDACi’s may have an
effect on cardiac remodeling indepen-
dent of inflammatory cytokines.
JOINT DISEASES
In addition to cytokine-driven loss of
the insulin-producing β cell, the chon-
drocyte is important in the production of
proteoglycans for maintenance of carti-
lage integrity, but is a target for cytokine-
driven destruction (70). Overexpression
of IL-1β results in irreversible cartilage
destruction. ITF2357 is protective on car-
tilage catabolism in a mouse model of
nonautoimmune inflammatory arthritis
induced by Streptococcus pyogenes cell
walls. Administered orally at a dose of 1
and 10 mg/kg, ITF2357 suppressed joint
swelling (25). As reviewed by Joosten et
al. (25), there was an inhibition of chon-
drocyte proteoglycan synthesis of 44%
with 1 and 10 mg/kg ITF2357. Thus,
HDACi’s may be used to preserve carti-
lage to protect against osteoarthritis. It is
likely that modulation of IL-1β by
HDACi’s, as shown in several reports,
results in reduced inhibition of chondro-
cyte proteoglycan synthesis and hence in
a protective effect against cartilage catab-
olism during arthritis. As reviewed by
Joosten et al. (25), ITF2357 also protects
bone loss induced by IL-1β.
The proof of principle study to test the
hypothesis that HDACi’s would benefit
joint disease can be found in the observa-
tions of the trial of givinostat (ITF2357)
in children with SOJIA (5). ITF2357 is a
hydroxamic acid–containing, orally ac-
tive inhibitor targeting class I and II
HDAC. The children received a daily
dose of 1.5 mg/kg in two divided doses.
At a dose of 1.5 mg/kg, the peak blood
levels of ITF2357 were in the range of
125–200 nmol/L. There was no organ
toxicity, and the study achieved signifi-
cant (P < 0.01) reduction in parameters of
systemic disease as well as the number
of painful joints in over 75% of patients.
At week 4, the American College of
Rheumatology (ACR Pediatric) 30, 50 or
70 improvement was 77.8%, 55.6% and
22.2% and increased further to 77.8%,
77.8% and 66.7%, respectively, at week
12. The most consistent finding was the
reduction in the number of active joints
and/or joints with limited range of mo-
tion (5). Also, in that trial, there was a re-
duction in the white blood cell counts,
the percentage of neutrophils, the levels
of IL-1α and CD40 ligand as well as sedi-
mentation rate and CRP (26). After 12
weeks, givinostat resulted in significant
safety and benefits.
GRAFT VERSUS HOST DISEASE
After allogeneic bone marrow trans-
plantation in mice, treatment with
HDACi’s provides a survival benefit in
models of GvHD. Administration of
SAHA after bone marrow transplanta-
tion reduced intestinal histopathology,
clinical severity and mortality from acute
GvHD (71). Moreover, in mice receiving
lethal doses of tumor cells, administra-
tion of SAHA did not impair graft versus
tumor activity and resulted in signifi-
cantly improved tumor-free survival.
Similar observations were reported for
other HDACi’s such as ITF2357 (44). The
mechanism for these effects in GvHD
may be due to decreased cytokine pro-
duction, as was shown in those studies
(71). An early step in models of GvHD is
antigen maturation of dendritic cells.
Dendritic cells exposed to either SAHA
or ITF2357 increase the expression of
IDO, a suppressor of dendritic cell func-
tions (44). As reviewed by Choi and
Reddy (43) in this issue, acetylation of
STAT-3 activates its functions, and in-
deed HDACi’s activate STAT-3 by acety-
lation (72). With the acetylation of STAT-
3, there is downregulation of dendritic
cells. Therefore, HDACi’s likely serve
several functions in the prevention of
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GvHD. STAT-3 also promotes the tran-
scription of IDO. Thus, acetylation of
nonnuclear proteins such as STATs pro-
vides mechanistic insight into HDAC in-
hibition of cytokine production and im-
mune cell functions (72). In terms of
cellular mechanisms, inhibitors of HDAC
increase Fox-p3–expressing T-regulatory
cells, which contribute to the reduction
of disease in autoimmune models. SAHA
is presently in trials to prevent or reduce
disease severity in GvHD in patients
with bone marrow transplants. The topic
of HDACi’s in GvHD is reviewed in de-
tail in this issue (43).
WHERE DO HDACi’s FIT INTO THE
CURRENT TREATMENT OF CHRONIC
INFLAMMATORY DISEASES?
Joint, Bowel and Metabolic Diseases
As stated above, the antiinflammatory
properties of HDACi’s are based prima-
rily on a reduction in either the produc-
tion or the activity of inflammatory cy-
tokines in animals as well as in primary
cells at significantly lower concentrations
that those used in tumor cells. If
HDACi’s are to be used for treating
chronic inflammatory conditions,
HDACi’s should also inhibit the produc-
tion or activities of mediators such as ma-
trix metalloproteinases, cyclooxygenases,
adhesion molecules and chemokines. As
of this writing, the only clinical trial to
support the concept that a low dose of
HDACi’s exhibits antiinflammatory prop-
erties is the trial of ITF2357 in children
with SOJIA (5). ITF2357 (generic givinos-
tat) is a hydroxamic acid–containing,
orally active inhibitor targeting zinc-de-
pendent HDAC isoform class I and II
HDAC. On the basis of a reduction in the
secretion of IL-1β, givinostat was also
used to treat Schnitzler syndrome, as re-
ported in this issue of Molecular Medicine
(73). Vorinostat is presently in clinical tri-
als in patients with GvHD (43), on the
basis of animal models (44,71,72).
In addition to inhibition of the produc-
tion of inflammatory cytokines, HDACi’s
also inhibit cytokine post-receptor signal-
ing. For example, SAHA and ITF2357 re-
duce IL-1β-driven death of the insulin-
producing β cell in primary rat and
mouse islets and cell lines (6,32,35) as re-
viewed in this issue of Molecular Medicine
(34). Similar studies were reported for in-
hibition disease in animal models of
rheumatoid arthritis and osteoarthritis, as
reviewed in this issue (25). At first glance,
these are seemingly unrelated models. But
on closer examination, each has inflam-
matory cytokines as part of the pathologi-
cal mechanism. For example, there is a cy-
tokine pathway in established models of
inflammatory bowel disease (74), lupus
nephritis (75), chronic heart failure (63),
rheumatoid arthritis and osteoarthritis
(25), multiple sclerosis (76) and GvHD
(43). There is also a cytokine component
in traumatic brain injury (77). However, it
is unlikely that inflammation affects dis-
ease in muscular  dystrophy (78).
Atherosclerosis
More than any other chronic inflamma-
tory disease, atherosclerosis is the major
cause of death in the developed world
because of overnutrition and Type 2 dia-
betes; overnutrition is also a cause of
Type 2 diabetes in developing countries.
Because of their safety and ease of oral
administration, most patients at high risk
of a cardiovascular event are treated with
a “statin,” since these drugs have re-
duced the incidence of cardiovascular
events and deaths. The beneficial view of
statins is thought to be because of a com-
bination of their property to reduce low-
density lipoproteins (LDLs) as well as an-
tiinflammatory agents. By comparison,
HDACi’s could be ideal for reducing in-
flammation in the atherosclerotic plaque.
As pointed out in the review by Halili et
al. (79), little is known about the effects of
HDACi’s on the atherosclerotic process.
There are two mouse models of athero-
sclerosis: the apoenzyme E (APOE) and
the LDL  receptor–deficient mouse. To our
knowledge, there is one study in which
HDACi’s was used to treat these mice
and evaluate the effects.
LDL-deficient mice fed a high-fat diet
for 4 and 8 weeks and treated with TSA,
a specific histone deacetylase inhibitor
for HDAC-1 and HDAC-2, revealed no
reductions in atherosclerotic lesions (80).
In fact, treatment with TSA worsened the
disease. TSA was injected intraperi-
toneally every other day at 0.5 and
1.0 mg/kg and, as stated by the authors,
at “doses used to treat tumors in mice”
(80). The 50% inhibitory concentration of
TSA for HDAC-1 is 2 nmol/L and for
HDAC-2 is 3 nmol/L (7). Thus, these
doses are likely to be considerably higher
than those required to suppress inflam-
mation. In vitro, acetylation of H4 in
mouse macrophages was observed at
10 ng/mL (33 nmol/L), which is 10-fold
greater than the IC50 for HDAC-2 (80).
Cyclooxygenase-2 (COX-2) is consid-
ered proatherogenic, and COX-2 expres-
sion is in increased bone marrow–
 derived mouse macrophages treated
with SAHA or TSA. Similarly, plasmino-
gen activator inhibitor-1 (PAI-1) is also
proatherogenic, and its expression is in-
creased in the same macrophages treated
with SAHA or TSA (81). However, the
concentration of SAHA added to these
cultures was 10 μmol/L, which is 100-
fold higher than the IC50 for HDAC-1
and 75-fold higher than that for HDAC-2
(7). In mouse macrophages stimulated
with LPS, PAI-1 protein levels increase
over 10-fold when incubated with TSA;
however, the concentration of TSA used
in those studies was 500 nmol/L, which
is a 250-fold higher concentration than
the IC50 for HDAC-1 (81). Similarly,
COX-2 increased over 40-fold in the pres-
ence of 500 nmol/L TSA, which is 250-
fold over the IC50 for TSA on HDAC-1.
Importantly, at 10 nmol/L TSA, which is
only three-fold greater than the IC50,
there was no increase in COX-2 expres-
sion in LPS-stimulated macrophages (81).
In addition, an increase in PGD2 by
HDACi inhibits the production of IL-1-
induced metalloproteinases (82). In con-
trast, Yamaguchi et al. (83) reported that
HDACi’s block the induction of c-jun
transcription by inhibiting the recruit-
ment of the complex to the c-jun pro-
moter. This results in reduced expression
of several activator protein-1– dependent
genes, including COX-2.
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Similar data can be found in an earlier
report. Bone marrow–derived mouse
macrophages were stimulated with LPS
and at various time points, HDAC-1,
HDAC-4, HDAC-5, HDAC-7, HDAC-8
and HDAC-9 were elevated (84). Of
these, HDAC-1 exhibited the greatest in-
crease and duration. TSA at a concentra-
tion of 500 nmol/L was examined for its
effects on LPS-induced genes. With use
of microarray analysis of LPS-inducible
genes, one group was unaffected, an-
other was superinduced and a third
group was suppressed. The genes that
were suppressed were not revealed in
the report. Of those genes that were su-
perinduced, COX-2 mRNA and protein
increased. A similar increase was ob-
served for the chemokine CXCL2 and
endothelin (84). The authors concluded
that HDACs act as negative regulators of
LPS-induced COX-2 (84). In support of
this concept, mouse macrophages were
transfected with the proximal promoter
of COX-2, and LPS increased the activity
of the promoter five-fold. In the pres-
ence of TSA (500 nmol/L), the increase
was 18-fold (84).
The findings of increased IFNγ and
TNFα production in the study in NOD
mice (36), the exacerbation of atheroscle-
rosis in the LDL-deficient mouse (80),
the increases in VCAM-1 and scavenger
receptor CD36 (80) in COX-2 (81, 84) and
elevated PAI-1 (81) by TSA and SAHA in
mouse macrophages are inconsistent
with the overall portfolio of antiinflam-
matory properties of HDACi’s. How
does one explain the discrepancies?
Using in vitro concentrations of TSA of
500 nmol/L is certainly inconsistent
with the low concentration of this
HDACi with an IC50 for HDAC-1 and
HDAC-2 of 2 and 3 nmol/L, respectively
(7). LDL receptor–deficient mice were
treated with 1 or 0.5 mg/kg of TSA
every other day, the dose used to treat
tumors in mice. In the case of studies
with TSA, one cannot predict the rele-
vance for human disease, since there are
no studies on the blood levels of TSA
after intraperitoneal injections, and the
toxicity of TSA in humans will likely
never be known. It is interesting to note
that the beneficial effect of TSA in the
NOD model was achieved at a dose of
0.5 mg/kg once weekly. However, the
reduction in diabetes was only observed
when the treatment was limited to the
interval of 18–24 weeks of age (36),
whereas early treatment at 5–18 weeks
of age was without effect. In the LDL
 receptor–deficient mouse, for inducing
atherosclerosis, the dose was 1.0 mg/kg
every other day. One may conclude that
the antiinflammatory properties of
HDACi’s are best observed at low dos-
ing schedules and that few conclusions
can be drawn by using antitumor doses
in mice. However, one may also inter-
pret from these data that treating ro-
dents with HDACi’s in models of dis-
ease requires higher doses than in
humans.
Unlike TSA, there are ample data in
studies with SAHA, FK228 or ITF2357 in
humans. Blood levels and tolerability
have been established. In the case of
SAHA, the maximal tolerated dose of
800 mg/day in two divided doses in-
duces fatigue, nausea and some vomiting
(85,86). In the report by Halili et al. (81),
SAHA increased gene expression of
COX-2, PAI-1 and IL-12 in mouse
macrophages at 10 μmol/L, a concentra-
tion 100-fold greater than the IC50 for
HDAC-1 (7), which is clinically irrele-
vant. In vitro, SAHA reduces LPS-
 induced cytokines in primary human
PBMCs at concentrations between 50 and
200 nmol/L, far lower than the 10 μmol/L
used by Halili et al. The concentration of
10 μmol/L in vitro is used to induce
proapoptotic genes in tumors. For
ITF2357, there is tolerability in healthy
humans (87), in patients with autoin-
flammatory diseases (73) and in children
with SOJIA (5). At an oral dose of 
1.5 mg/kg, ITF2357 (givinostat) is well
tolerated. At this dose, there is a transient
reduction in LPS-induced cytokines in
whole blood cultures during a phase I trial
in healthy humans, and this reduction oc-
curs at a blood level of 125–250 nmol/L,
concentrations known to inhibit LPS-
 induced cytokines in PBMCs (11,87). In
patients with SOJIA, clinical and hemato-
logical improvement is observed at this
low dose (5,26) and similarly in patients
with Schnitzler syndrome (73). It ap-
pears that HDACi’s such as ITF2357
(givinostat) may be candidates for treat-
ing chronic inflammatory diseases in-
cluding atherosclerosis.
TREATING ACUTE DISEASES WITH
HDACi’s
Studies have focused on mouse mod-
els of sepsis, but it is unlikely that
HDACi’s will be tested in clinical trials
for human sepsis. HDACi’s have also
been tested in models of ischemia/reper-
fusion (88,89). Ischemia/reperfusion is
essentially sterile inflammation, and,
here, cytokines such as IL-1α and TNFα
play a significant role. But the testing of
HDACi’s in humans with hemorrhagic
shock, acute stroke or myocardial infarc-
tion is doubtful. One recurrent acute dis-
ease is gout and, here, HDACi’s may
provide an additional benefit to
colchicine, as studies demonstrate that
gout is highly responsive to IL-1β block-
ade (90–92).
NEURODEGENERATIVE DISEASES
Neurodegeneration includes the slow
progressive forms characteristic of ather-
osclerotic brain disease as well as Alz-
heimer disease but also that following
acute brain trauma of a stroke or blunt
injury. Histone deacetylation is often al-
tered in the brains of animals used to
study neurodegeneration. In this issue,
Shein and Shohami (77) review the evi-
dence for the use of HDACi’s in treating
either the acute or slowly progressive
course of neurodegeneration. The effi-
cacy of HDACi’s in acute brain injury
was reported by Shein et al. (93) as well
as in models of amyotrophic lateral scle-
rosis (ALS), Alzheimer disease, spinal
muscular atrophy and experimental au-
toimmune encephalomyelitis. Although
many neurodegenerative diseases in-
clude a cytokine-driven inflammatory
component, Huntington disease remains
a uniquely noninflammatory loss of neu-
rons. Nevertheless, several models of
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neurodegeneration are due to inflamma-
tory processes. In this regard, the antiin-
flammatory properties of HDACi’s ap-
pear to be neuroprotective. In animal
models of Alzheimer disease, the most
studied neurodegenerative disease,
HDAC inhibition decreased β-amyloid
production and effective neuroprotection
was associated with increased acetyla-
tion of histone 4 (94). In a model of
closed head trauma, the antiinflamma-
tory properties of HDACi’s prevented
the deterioration of neurological impair-
ment, even when administered 24 hours
after the injury (93).
Huntington Disease
Although the role of inflammation in
Huntington disease is presently unclear,
inhibition of caspase-1 delays the onset
of motor abnormalities in a mouse model
of the disease (95) and treatment with
oral SAHA also reduced disease severity
(96). Because the effect of valproic acid
on the central nervous system is well
documented, clinical trials with oral
HDACi’s could be initiated in patients
with early indications of dementia. Al-
though currently available HDACi’s are
“pan HDAC” inhibitors, HDACi’s with
greater specificity will be the future di-
rection for this class of drugs.
Huntington disease is an autosomal-
dominant genetic disease. The patholog-
ical lesions occur in the striatum and
cortex and the disease is fatal approxi-
mately 20 years after the onset of symp-
toms. There is an expanded CAG/
polyglutamine repeat in “huntingtin,” a
protein of unknown function. The dis-
ease is progressive with loss of motor
function, and there is no treatment to
slow the progress of the disease. In
2003, there was a report that SAHA
added to the drinking water of R6/2
HD mice, the model for this disease, re-
sulted in marked improvement in motor
function (96). Transgenic mice express-
ing human huntingtin with an ex-
panded CAG/ polyglutamine repeat de-
velop a progressive syndrome with
many of the characteristics of human
Huntington disease (95). Indeed, SAHA
crosses the blood-brain barrier and in-
creases histone acetylation in the brain
(96). The administration of SAHA has
consistently shown this therapeutic ben-
efit in the mouse model; nevertheless,
which HDAC is affected by SAHA to
improve motor function in the R6/2
mouse model remains unclear. Brain
levels of HDAC-7 are reduced in both
wild-type animals and in animals with
SAHA (97). However, there was no im-
provement in a number of physiological
or behavioral phenotypes in R6/2 mice
deficient in HDAC-7 (97). Thus, the
SAHA-mediated amelioration or disease
severity in the mouse model for Hunt-
ington disease is not via HDAC-7, and
the ability of SAHA to reduce brain lev-
els of HDAC-7 appears to be unrelated.
Intracerebroventricular administration
of a caspase inhibitor delays disease pro-
gression and mortality in the transgenic
mouse (95). In a rat cerebral artery occlu-
sion model of stroke, post-insult treat-
ment with the HDACi valproic acid re-
duced ischemia-induced brain infarction,
caspase-3 activation and neurological
deficits (98). In a rat excitotoxic model of
Huntington disease, treatment protected
against DNA damage, caspase activation
and apoptosis of striatal neurons (98).
Thus, HDACi’s are potential drugs for
treating some forms of neurodegenera-
tive diseases, and whether the benefit of
HDACi’s is via a cytokine-mediated pro-
cess such as caspase-1 remains to be
demonstrated. In neurons, acetylation at
lysine 40 of α-tubulin increased by TSA
results in the release of the brain- derived
neurotrophic factor (99). Tubulin acetyla-
tion is reduced in the brains of animals
with Huntington disease, and TSA com-
pensates for the transport- and release-
defect phenotypes that are observed in
disease (99).
Amyotrophic Lateral Sclerosis
ALS is another disease in which there
is progressive loss of brain neurons. A
study in mice with mutations in super -
oxide dismutase revealed a role for
 caspase-1 processing of IL-1β. The mouse
model for ALS is G93A-SOD1, a trans-
genic mouse expressing mutant superox-
ide dismutase 1 (SOD1). Mutant SOD1
activates caspase-1 and IL-1β in microglia
(100) and supports the concept that neu-
roinflammation contributes to ALS dis-
ease progression (101). Mutant SOD1-
 induced IL-1β correlated with amyloid-like
misfolding and was independent of dis-
mutase activity. ALS-linked cytoplasmic
accumulation of mutant SOD1 was sensed
by an apoptosis-associated speck-like
protein containing a C-terminal caspase
recruitment domain (ASC)-containing
 inflammasome and antagonized by
 autophagy, limiting caspase-1–mediated
inflammation (100). A deficiency in
 caspase-1 reduced IL-1β levels, extended
the lifespan of G93A-SOD1 transgenic
mice and attenuated inflammatory
pathology. Similar results were observed
with treatment with recombinant IL-1Ra
(100). These findings identify microglial
IL-1β as a causative event of neuroinflam-
mation and suggest IL-1 as a potential
therapeutic target in ALS (101).
IS THERE A ROLE FOR CYTOKINE
INHIBITION IN MULTIPLE MYELOMA?
The cytokine IL-6 is the primary growth
factor for myeloma, and anti–IL-6 mono-
clonal antibodies as well as anti–IL-6 re-
ceptor monoclonal antibodies are used to
treat Castleman disease. However, in pa-
tients with a premyeloma condition called
smoldering or indolent myeloma, block-
ing IL-1β to reduce IL-6 production signif-
icantly prevents progression to full-blown
multiple myeloma (102,103). HDACi’s in-
hibit the production of IL-6 by LPS as
well as IL-1β-driven IL-6 (10,11,23,24).
Therefore, although multiple myeloma is
cancer, the use of HDACi’s in the precan-
cer condition of smoldering/indolent my-
eloma is a likely therapy compared with
the daily injection of anakinra that was
used in the trial (102).
The activity of ITF2357 was studied on
multiple myeloma and acute myeloge-
nous leukemia cells in vitro and in vivo.
ITF2357 induced apoptosis in freshly ob-
tained multiple myeloma and acute
myelogenous leukemia cells at an IC50 of
200 nmol/L (104). ITF2357 induced hy-
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peracetylation of histone H3, H4 and
tubulin. ITF2357 was also cytotoxic for
the IL-6–dependent multiple myeloma
cell line CMA-03. Of particular relevance,
ITF2357 inhibited the production of IL-6,
vascular endothelial growth factor and
IFNγ by mesenchymal stromal cells by
80–95% (104). In vivo in mice, ITF2357 sig-
nificantly prolonged survival of severe
combined immunodeficient mice inocu-
lated with acute myelogenous leukemia
cells at a dose of 10 mg/kg and inhibited
the production of growth and angiogenic
factors by bone marrow stromal cells, in
particular IL-6 and VEGF (104). These re-
sults suggest that part of the mechanism
of action of HDACi’s in multiple mye-
loma and acute myelogenous leukemia
may be due to a reduction in cytokine
production, since these hematopoietic
malignancies are driven by IL-1β and
IL-6 as growth factors (102,105,106). A
phase II, multiple-dose clinical trial in 19
patients with relapsed or progressive
multiple myeloma was carried out (107).
The first six patients received 150 mg
ITF2357 twice daily, but because of toxic-
ity, the dose was reduced to 100 mg
ITF2357 twice daily. This was the maxi-
mal tolerated dose. Although these pa-
tients had advanced disease, a dose of
100 mg twice daily alone or combined
with dexamethasone, ITF2357 proved tol-
erable and showed a modest clinical ben-
efit (107). It appears that the optimal use
of HDACi’s in multiple myeloma would
be in smoldering myeloma, where the
combination of IL-1β blockade plus dex-
amethasone significantly delays or even
prevents the progression to full-blown
multiple myeloma (102).
Gene expression profiling of the
KMS18 multiple myeloma cell line was
performed with ITF2357 (108). The mod-
ulation of several genes and their biolog-
ical consequence were verified in a panel
of multiple myeloma cell lines and cells
freshly isolated from patients by using
polymerase chain reaction analysis and
Western blotting. Out of 38,500 human
genes, several were downregulated and,
in particular, ITF2357 down-modulated
the IL-6 receptor α transcript and protein
in both cell lines and freshly isolated pa-
tient cells (108). The decrease in the IL-6
receptor expression was accompanied by
decreased signaling, as measured by
STAT-3 phosphorylation. These data sup-
port the previous studies that ITF2357 in-
hibits cytokine-mediated myeloma cell
growth and survival.
IS THERE A ROLE FOR CYTOKINE
INHIBITION IN MYELOPROLIFERATIVE
DISORDERS?
The efficacy of givinostat in 12 patients
with polycythemia vera and in 16 pa-
tients with myelofibrosis, bearing the
JAK2V617F mutation, has been reported
(109). Givinostat was given orally for 24
weeks at a dose of 50 mg twice daily;
however, a dose reduction was applied
in 10 patients. The median treatment du-
ration was 20 weeks. The troubling puri-
tus disappeared in most patients, and re-
duction of splenomegaly was observed
in 75% of polycythemia vera patients
and 38% of myelofibrosis patients. Re-
verse transcription polymerase chain re-
action identified a trend to reduction of
the JAK2V617F allele burden. Givinostat
was well tolerated and could induce
hematological response in most poly-
cythemia vera patients (109). In vitro, the
effect of ITF2357 was evaluated on carry-
ing the JAK2 (V617F) mutation obtained
from polycythemia vera and essential
thrombocythemia patients (110). The
clonogenic activity of JAK2 (V617F) mu-
tated cells was reduced by low concen-
trations of 1–10 nmol/L of ITF2357,
which is 100- to 250-fold lower than con-
centrations that are traditionally required
to inhibit the growth of tumor cells lack-
ing this mutation. By Western blotting,
ITF2357 resulted in the disappearance of
total and phosphorylated JAK2 (V617F)
as well as pSTAT5 and pSTAT3 (110).
Together, these studies provide evi-
dence that, in some hematopoietic disor-
ders, the efficacy of HDACi’s is in part
due to a reduction in either cytokine pro-
duction or cytokine signaling. Clinically,
acute myelogenous leukemia, poly-
cythemia vera and multiple myeloma are
associated with elevated CRP and mark-
ers of systemic inflammation such as re-
current fevers. The low concentrations in
vitro and in vivo also support the concept
that the cytokine-reducing properties of
HDACi’s contribute to controlling dis-
ease activity rather than direct tumor cell
death. To accomplish tumor cell death,
dexamethasone or another proapoptotic
regimen is required.
CUTANEOUS T-CELL LYMPHOMA
Two HDACi’s, vorinostat and ro-
midepsin, are approved for the treatment
of cutaneous T-cell lymphoma (CTCL). It
is likely that there is a role for cytokines
in this disease. The levels of IL-1α in epi-
dermis of patients with CTCL was inves-
tigated by using immunohistochemistry
and specific enzyme-link immunosorbent
assays. Significant increases of IL-1α
were released from the involved CTCL
epidermis compared with the normal
epidermis from healthy individuals (111).
Both keratinocytes and leukocytes could
release IL-1α, but the majority was de-
rived from the keratinocytes. The IL-1α
was biologically active (111). Extracorpo-
real photopheresis is used to treat CTLC.
Following this therapy, lymphocytes be-
come apoptotic and monocytes, exposed
to post-extracorporeal photopheresis
(post-ECP), reduce spontaneous proin-
flammatory cytokine secretion including
IL-1α (112). IFNγ is commonly used to
treat CTLC. The mechanism of action 
of IFNγ in CTLC may include the induc-
tion of IL-1Ra (113). SAHA as well as
givinostat do not suppress IL-1Ra (11)
and, in some studies, increase the pro-
duction of IL-1Ra (87).
SAFETY AND TOLERABILITY
REQUIREMENTS OF HDACi’s FOR
TREATING CHRONIC DISEASES
When considering the property of
HDACi’s in the treatment of chronic dis-
eases characterized by inflammatory, au-
toimmune or degenerative processes, use
of HDACi’s to treat such diseases is safe
and well tolerated. In general, HDACi’s
are safe in humans. For example, val-
proic acid, a carboxylate HDACi, is the
drug of choice for chronic therapy of
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generalized and focal epilepsy as well as
obsessive disorders (114,115). Valproic
acid has also been used to increase latent
HIV-1 gene expression in patients while
being treated with anti–HIV-1 drugs
without interference (116). Butyrates are
used to treat patients with sickle cell ane-
mia and β-thalassemia (117). In fact, val-
proic acid is used chronically by millions
of people. SAHA (vorinostat) is presently
being evaluated for treatment in GvHD
(71). ITF2357 (givinostat) has been used
in children with SOJIA for 12 weeks
without adverse effects (5,26). Givinostat
has also been tested in patients with the
autoinflammatory disease Schnitzler syn-
drome, and the observations are reported
in this issue (118). In both the SOJIA and
Schnitzler syndrome studies, there were
clear indications of the desired antiin-
flammatory effects in that clinical scores
of disease severity as well as a decrease
in the circulating number of white blood
cells occurred. In both studies, the dose
of 1.5 mg/kg was well tolerated.
Chronic diseases that are likely to be
treated with HDACi’s are rheumatoid
arthritis, osteoarthritis, inflammatory
bowel disease and Type 2 diabetes and,
being orally effective, HDACi’s have
considerable advantages over the par-
enterally administered anticytokines.
These diseases are dramatically affected
by anticytokine antibodies and soluble
receptors, which have no organ toxicities
other than the pain of the injection
needle; indeed, they are remarkably well
tolerated. In contrast, HDACi’s do have
organ toxicities and, at doses used to
treat cancer, all HDACi’s cause gastroin-
testinal disturbances and other constitu-
tional symptoms. These constitutional
symptoms would not be tolerated in pa-
tients without life-threatening cancer. If
clinical trials of HDACi’s are proven to
reduce activity in chronic diseases, they
will need to be well tolerated. Therefore,
the dose required to reach an effective
tissue level should be without significant
constitutional symptoms. It also remains
unclear whether HDACi’s will be used
as a monotherapy or in combination
with other antiinflammatory agents such
as glucocorticoids. In the children with
SOJIA, givinostat was used in combina-
tion with steroids.
In assessing the effects of various
HDACi’s in animal models of disease,
one must establish that any beneficial ef-
fect in the model is consistent with a
dose that is likely to be tolerated in hu-
mans. In many models, TSA is used to
assess a role for HDACi’s in the amelio-
ration of disease activity. For example,
TSA in models of lupus nephritis TSA
was administered for 5 weeks at a dose
of 0.5 mg/kg/day with a clear beneficial
effect (119). However, it is impossible to
draw any conclusions as to whether the
tissue concentrations of TSA required 
for the effect of TSA are in the range of
clinically relevant HDACi’s. In this
model of lupus nephritis, mice were also
treated with SAHA at a dose of 25 and 
50 mg/kg intraperitoneally for 10 weeks
(120). In humans with leukemia, the
maximum tolerated dose for SAHA was
200 mg twice daily (1.5 mg/kg twice a
day) (85). Dose- limiting toxicities were
fatigue, nausea, vomiting and diarrhea.
Even assuming that the mouse requires a
10-fold greater amount of SAHA than
humans to reach the effective concentra-
tion in vivo, SAHA at doses of 2.5 mg/kg
was not well tolerated.
On the other hand, the use of HDACi’s
gained considerable validity when the ef-
fective concentration in vitro was attain-
able in humans after oral administration.
In the phase I trial of givinostat in healthy
male subjects, a single oral dose of 
100 mg resulted in a peak plasma level 
of 207 nmol/L at 2 hours and an area
under the curve (AUC) of 1,410 nmol/L/h
with a half-life of 6 hours (87). In vitro, 
100 nmol/L of ITF2357 (givinostat) sup-
pressed by 90% IL-1β-driven loss of bone
in the rat calvarium model for osteoclast
activation and similarly for TNFα-driven
bone loss (25). The oral dose of 100 mg
also suppressed LPS-induced TNFα, IL-1β
and IFNγ 4 hours after dosing. In freshly
obtained human PBMCs, concentrations
of 12.5 to 25 nmol/L of ITF2357 were
 observed for IC50 of LPS-induced TNFα,
IL-1β and IFNγ.
MUSCULAR DYSTROPHY
As reviewed in this issue of Molecular
Medicine (78), HDACs regulate muscle-
specific gene transcription via control of
histone acetylation. Thus, the balance
between acetylation and deacetylation is
a critical determinant of muscle gene
transcription and is emerging as a possi-
ble intervention for the regenerative po-
tential of muscle stem cells. For muscu-
lar dystrophy, Consalvi et al. (78)
showed that the mechanism responsible
for the activity of HDACi’s in the animal
model of muscular dystrophy goes be-
yond follistatin induction. There is the
known potential of dystrophic muscles
to activate mechanisms of compensatory
regeneration. This evidence supports the
current view that HDACi’s are emerging
candidate drugs for pharmacological in-
terventions in muscular dystrophies and
reveals unexpected common beneficial
outcomes of pharmacological treatment.
The activation of a differentiating pro-
gram in the stem cells resident in the
muscle is a further key mechanism that
contributes to the activity of these com-
pounds. Differentiation of stem cells to-
ward a specific lineage through epige-
netic modulation has a potential in
many field of medicine. With safety on
its side, it is possible that a clinical trial
of HDACi’s may result in activating
stem cells to differentiate into muscle
cells, but the specificity of HDAC and
cofactors for differentiation are not
presently established.
AUTOPHAGY AND HDACi’s
Autophagy
In general, autophagy is an adaptive
mechanism protecting the loss of cells by
reusing intracellular components that
have been generated by pathological
processes. Autophagy is often studied in
vitro in cells deprived of nutrients, but in
vivo, autophagy replenishes cells after an
ischemic or stressed event and prolongs
their function. Autophagy is also observed
in yeasts, and the weak HDACi valproic
acid increases autophagy in yeasts under-
going the stress of DNA breaks (121).
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Without this mechanism, cells die with in-
tracellular debris and organs fail. In some
disease processes, autophagy can be mal-
adaptive for the host, and this is certainly
the case in malignant cells. HDACi’s func-
tion in the treatment of cancer by increas-
ing genes that inhibit autophagy.
In diabetes, autophagy is a protective
process (122,123). Endogenous proteins
that are trapped in the endoplasmic retic-
ulum (ER) result in ER stress. In the
 insulin-producing pancreatic β cell, ER
stress can occur because of a failure to re-
lease insulin into the extracellular com-
partment after glucose load and die an
apoptotic death. Cells producing IL-1β
such as the β cell itself have an additional
threat related to caspase-1, that is, the pro-
cessing of the IL-1β precursor and release
of active IL-1β. Active IL-1β can then trig-
ger the IL-1 receptor type I (IL-1RI) lead-
ing to NO production and cell death.
HDACi’s reduce IL-1β processing and re-
lease and therefore are of potential use in
protecting the β cell and thus are a treat-
ment possibility in diabetes.
HDACi’s and the Failing Heart
Although autophagy benefits the
 insulin-producing β cell, autophagy is
maladaptive in left-side ventricular hyper-
trophic heart disease (124). In the stressed
ischemic heart, the autophagic process at-
tempts to prevent loss of the myocyte and
reuse the intracellular debris generated
during the ischemic event. Inhibition of
autophagy would seem counterproductive
for an ischemic heart. HDACi’s do, in fact,
inhibit autophagy, and therefore their use
would be counterproductive in rescuing
cells from death. However, in hyper-
trophic left ventricle heart failure, prevent-
ing autophagy is beneficial, since it re-
duces the proliferation. In many cases of
heart failure, there is a constriction of the
aortic outflow, and the hypertrophic left
ventricle undergoes a proliferative re-
sponse, which is necessary to compensate
for the restriction. The benefit of HDACi’s
in this form of heart failure is not the case
in right side heart failure due to pressure
overload. Suppression of histone deacety-
lases worsens right ventricular dysfunc-
tion after pulmonary artery banding in
rats via a mechanism of decreased angio-
genesis and eNOS expression (125).
Whereas HDAC inhibition reduces left
ventricular hypertrophy, fibrosis and apo-
ptosis, the opposite effects of HDACi
treatment were observed with pressure
overload of the right ventricle (125). It is
unclear from that study of pulmonary
banding–induced right ventricular failure
if lower doses of TSA would have yielded
the same data in vivo. In vitro, 300 nmol/L
TSA was required to reduce eNOS and
VEGF in cultured human cardiac mi-
crovessel endothelial cells, a concentration
100-fold greater for the IC50 of TSA for
HDAC-2 and 150-fold greater for HDAC-1
(7). However, these authors are correct in
that HDACi’s do reduce angiogenesis, as
we have observed blood vessel formation
in Matrigel plugs embedded with 10 ng
IL-1β in mice treated with 2.5 mg/kg oral
ITF235 (unpublished data).
Left ventricular hypertrophy takes place
as a compensatory mechanism to restore
functionality in conditions of increased af-
terload or wall stress (that is, after an is-
chemic event). Left ventricular hypertro-
phy is an unfavorable prognostic factor
and represents a major clinical problem af-
fecting millions of patients worldwide. In-
deed, the concept has been tested in
mouse models of left ventricular hypertro-
phy. The study used phenylephrine-in-
duced hypertrophic growth and was pre-
vented by treatment with TSA (124). Other
HDACi’s reduced hypertrophic growth in
cultured cardiomyocytes. Hypertrophic
agonist–induced autophagy is suppressed
in neonatal cardiomyocytes in culture
when treated with the hypertrophic ago-
nists in the presence of TSA (66 nmol/L)
or valproic acid (6 mmol/L) (124). To
demonstrate the role of autophagy in the
hypertrophic cardiomyocyte growth, ex-
pression of endogenous ATF5, the gene
that is essential for autophagic protection,
was suppressed with inhibitory RNA and
resulted in reduced cardiomyocyte growth
in vitro. The ability of HDACi’s to inhibit
autophagy appeared to target HDAC-1
and HDAC-2 (124); thus, HDAC-1 and -2
contribute to maintaining autophagy. To
show the utility of these studies, the au-
thors treated mice with established left
ventricular hypertrophy with TSA (1.0
mg/kg/day) and observed that ventricu-
lar function returned to normal levels
(124). Similar protective results of
HDACi’s were reported in animal models
of ischemic and nonischemic (doxoru-
bicin) myocardial injury (126,127). These
studies and the role of HDACi’s in heart
failure are reviewed by McKinsey (63) in
this issue. The data suggest that oral
HDACi’s may have a role in treating left
ventricular hypertrophy, while caution
should be used in cases of right ventricu-
lar hypertrophy.
HDACi’s AS A METHOD FOR HIV-1
ERADICATION
Since the introduction of highly active
antiretroviral therapy (ART) more than a
decade ago, HIV-1 infection can be well
controlled, and in nearly all treated pa-
tients, HIV-1 viremia remains below de-
tectable levels as long as therapy is sus-
tained. Indeed, ART has changed the face
of HIV-1. For example, after the initiation
of ART, markedly reduced CD4+ T cells
rose to near-normal levels, and death from
opportunistic infection was rarely ob-
served. As such, this formally fatal disease
has been transformed into a chronic dis-
ease. Nevertheless, lifespan, even in pa-
tients well controlled on ART, remains
below that of the general population. De-
spite the effectiveness of ART in suppress-
ing HIV-1 replication, after discontinua-
tion of ART, there is a rebound viremia,
which occurs typically after 2 weeks (128).
The source of viral reemergence is a long-
lived pool, most likely the latently infected
memory CD4+ T-cell reservoir, harboring
integrated HIV-1 proviral DNA (129). At-
tacking this latent pool remains a priority
in combating HIV-1 infections (130).
The latent reservoir of HIV-1 within
resting CD4+ cells is established early
after acute infection and is an extremely
stable reservoir, having a half-life of 
6–44 months, even in treated patients
who are continuously aviremic for long
periods of time (129). The integrated
proviral DNA is present in densely orga-
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nized nucleosomes; for viral replication,
transcription factors such as NFκB bind
to the long terminal repeat of HIV-1 and
drives expression of HIV-1 with release of
competent virus. During the process of
viral replication, the CD4+ T cells die, but
new CD4+ T cells are infected after the re-
lease of a competent virus. However, in
patients on ART, any newly released
virus cannot be integrated into the DNA
of naïve CD4+ T cells, since the activity of
reverse transcriptase and intergrases are
inhibited by the antiretroviral drugs. The
use of the chemokine/HIV-1 receptor an-
tagonists also prevents viral entry. To de-
plete the latent pool, activating the CD4+
T cell with IL-2 therapy in patients on
ART was tested in large clinical trials but
without a significant reduction. Another
approach is to force viral expression, by-
passing activation of the CD4+ T cells.
In latently infected CD4+ T cells,
HDAC-1 and HDAC-2 deacetylate local
histones, compact the chromatin and pre-
vent the binding of NFκB and other tran-
scription factors, and RNA polymerase II
binding does not occur. In vitro studies
demonstrated that activation of a latent
viral by NFκB reverses the repressive ef-
fect of the p50 homodimer HDAC-1 com-
plex by the binding of cytosolic NFκB
p50-RelA heterodimer. This step would
enable the recruitment of the histone
acetyltransferase, acetylation of the local
histones, relaxation of the chromatin and
initiation of viral transcription. Inhibition
of the enzymatic activity of HDAC-1 and
possibly other HDACs by HDACi’s re-
sults in activation of the HIV-1 long ter-
minal repeat, and viral expression is ob-
served in latently infected cells in vitro.
Because the HDACi valproic acid stim-
ulates HIV-1 expression in vitro, valproic
acid was tested in trials of HIV-1 in in-
fected patients while on continuous ART.
However, those trials did not yield the de-
sirable decrease in the latent reservoir
(116,131,132). It is believed that valproic
acid failed to have a significant impact be-
cause it is a nonspecific and weak HDACi.
Thus, whether the use of HDACi’s can
purge the virus from the latent reservoir
requires more potent agents. SAHA
(vorinostat) is more potent than valproic
acid, has greater specificity for HDAC-1
and HDAC-2 and is in clinical trials in
HIV-1-infected patients while taking ART
(131,133). As reported in this issue of
 Molecular Medicine, ITF2357  (givinostat)
appears to be more potent and specific
than vorinostat (19,38). We believe givino-
stat should be considered for a clinical
trial to force HIV-1 out of its latency and
gradually eliminate the  infection.
The hypothesis assumes that, with ex-
pression of HIV-1 from it latency, the in-
fected CD4+ T cell dies of a cytopathic
process and that the newly released virus
is incapable of being integrated into
naïve CD4+ T cells. As reported by
 Matalon et al. (19) and reviewed in this
issue (38), givinostat induces HIV-1 from
latently infected human macrophages
and T-cell lines at concentrations achiev-
able in humans and at doses that are
well tolerated. By comparison, to achieve
levels of vorinostat in vivo comparable to
the concentrations required to induce
HIV-1 expression in latently infected
human macrophage and T-cell lines, the
drug would likely not be well tolerated.
Similarly, to obtain the same level of
HIV-1 expression from these cell lines in
vitro, valproic acid concentrations in vivo
would not be well tolerated. Similar to
other treatment options of HDACi’s in
chronic diseases, as summarized in this
issue of Molecular Medicine, any disease-
modifying benefit of an HDACi must be
at a dose that is well tolerated.
THROMBOCYTOPENIA
HDACi’s used to treat malignant dis-
ease consistently induce thrombocyto-
penia. In fact, in addition to gastrointesti-
nal disturbances such as nausea and
diarrhea, a low platelet count appears to
be the major dose-limiting toxicity (134).
A fall in platelets has also been observed
in healthy subjects during a phase 1
study of givinostat in healthy subjects
(87). In that study, there was no concomi-
tant use of chemotherapy or radiation, as
is often the case with cancer patients re-
ceiving HDACi’s. In subjects treated with
daily dosing of givinostat for 7 days, a re-
duction in platelet count was observed
across all doses. The effect was evident
from day 5 onward, reaching the lowest
value on day 9, that is, 48 hours after last
dosing. On day 9, the mean platelet
counts decreased by 17%, 25% and 35%
in groups receiving givinostat at 50, 100
and 200 mg each day, respectively. For
the most part, the effect on platelets re-
covered on day 14 (7 days after last dos-
ing). In children treated with  givinostat
for 12 weeks at a dose of 1.5 mg/kg in
two divided doses, there was a fall in
platelets; however, disease activity in
SOJIA includes thromocytosis, and fall in
platelets is interpreted as beneficial. Nev-
ertheless, at a dose of 1.5 mg/kg, platelet
count remained in the normal range.
For givinostat, a dose between 1.0 and
1.5 mg/kg in two divided doses is well
tolerated and unlikely to reduce platelets
to below the normal range. If a particular
HDACi is well tolerated in terms of not
inducing constitutional symptoms related
to gastrointestinal disturbances or de-
creasing daily functions, a fall in platelets
in the range of 15–20% is without clinical
significance. Nevertheless, regardless of
the dosing schedule, any use of HDACi’s
for treating a chronic disease will require
monitoring of platelet counts.
The fall in platelets is not due to bone
marrow suppression. The HDACi ro-
midepsin (FK228) is approved for the
treatment of cutaneous T-cell lymphoma
and is selective for HDAC-1 and -2
(135). In examining the mechanism for
the reduction in platelets, it was con-
cluded that romidepsin in mice is not
myelosuppressive and does not reduce
the lifespan of platelets (134). Rather,
studies with romidepsin demonstrated
that HDACi’s are more likely to cause a
reduction in platelets because of the im-
paired release of platelets from the
megakaryocytes. In the romidepsin
study, primary megakaryocytes from
mice showed reductions in proplatelet
extensions with an increase in the phos-
phorylation of myosin light chain 2
(134). Of particular interest in that study
was the observation that that the
HDACi-induced thrombocytopenia in
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mice was prevented by coadministration
of a thrombopoietin mimetic (134).
SUMMARY
Studies in animal models have re-
vealed the unexpected observations that
HDACi’s can be used to reduce severity
in a broad range of diseases. For the
most part, the spectrum of diseases is in-
flammatory; and hence HDACi’s exhibit
antiinflammatory properties owing to a
reduction in cytokine production as well
as inhibition of cytokine effects. Distinct
from their use in cancer, the effects of
HDACi’s are consistently observed at
low concentrations compared to higher
concentrations required for killing tumor
cells. HDACi’s are therefore attractive as
a therapeutic option for suppressing
 inflammation.
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